The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

(2019) A.J. Scheen   DIABETES & METABOLISM

Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors

(2019) Susan J. Bersoff-Matcha et al.   ANNALS OF INTERNAL MEDICINE

The use of GLP‐1 receptor agonists in hospitalised patients: an untapped potential

(2019) O.G. Mustafa et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

An update on the safety of SGLT2 inhibitors

(2019) André J Scheen   Expert Opinion On Drug Safety

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

(2019) Alex Ali Sayour et al.   Journal of Translational Medicine

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence

(2019) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects

(2019) Motoaki Sano et al.   CIRCULATION

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction

(2019) Nannan Zhang et al.   Cardiovascular Diabetology

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital

(2019) Deepak Kana Kadayakkara et al.   PLoS One

Cardiovascular outcome trials of the newer anti-diabetic medications

(2019) Tushar Acharya et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations

(2018) D. A. Milder et al.   ANAESTHESIA

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

(2018) M. V. Karg et al.   Cardiovascular Diabetology

The effect of dapagliflozin treatment on epicardial adipose tissue volume

(2018) Takao Sato et al.   Cardiovascular Diabetology

The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest

(2018) Sebastian Wiberg et al.   CRITICAL CARE MEDICINE

Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

(2018) Milton Packer   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group

(2018) A. Roberts et al.   DIABETIC MEDICINE

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale

(2018) Yoshiaki Kubota et al.   Diabetes Therapy

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.

(2018) Hiroto Oshima et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

(2017) Tsung-Ming Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

(2017) James L. Januzzi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

(2017) Kelly R. Burke et al.   PHARMACOTHERAPY

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure

(2017) Milton Packer et al.   JAMA Cardiology

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

(2017) Jiali Liu et al.   Scientific Reports

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

(2016) Ronald M. Goldenberg et al.   CLINICAL THERAPEUTICS

Diabetes and Prediabetes and Risk of Hospitalization: The Atherosclerosis Risk in Communities (ARIC) Study

(2016) Andrea L.C. Schneider et al.   DIABETES CARE

Recurrent euglycemic diabetic ketoacidosis after discontinuation of sodium-glucose cotransporter 2 inhibitor

(2016) Spyridoula Maraka et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

(2016) Yehuda Handelsman et al.   Endocrine Practice

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice

(2015) Yusuke Kashiwagi et al.   PLoS One

Inhibiting Mitochondrial Na + /Ca 2+ Exchange Prevents Sudden Death in a Guinea Pig Model of Heart Failure

(2014) Ting Liu et al.   CIRCULATION RESEARCH

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes

(2014) Jaime A. Davidson et al.   POSTGRADUATE MEDICINE

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes: A pilot, randomized, controlled study

(2013) G. E. Umpierrez et al.   DIABETES CARE

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

(2013) N. Inagaki et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE